VitroScan and Imuno are awarded a MIT grant to develop a platform to de-risk clinical development of immunotherapy for bladder cancer patients!

27 January 2023

We are are proud to announce that VitroScan and Imuno have been awarded the MIT R&D-Samenwerkingsproject Trial Booster (€992.600) by the province Zuid-Holland! VitroScan and Imuno will leverage their technologies to develop a platform to de-risk clinical development of immunotherapy for bladder cancer patients. We will closely collaborate with clinical partners from the ErasmusMC bladder cancer center and drug developers.
Successful development of immunotherapy is challenging with a success rate of only 3.8%, while such therapies could potentially bring great value to patients. Therefore, we will develop VitroScans predictive ex vivo tumor testing platform and Imuno's predictive platform to identify bladder cancer specific neoepitopes and explain patients sensitivity to immunotherapies. We will offer services to pharma companies and clinical research organizations to de-risk clinical development of novel immunotherapy compounds. Our innovation will increase the efficiency and success rate of clinical studies on immunotherapy and will ensure that promising therapies reach bladder cancer patients that benefit.